<a href="https://laohu8.com/S/IGC">IGC Pharma</a> Reports Lower Revenue Amid Shift to Alzheimer's Drug Development
IGC Pharma Inc. reported revenue of approximately $191.0 thousand for the three months ended September 30, 2025, down from $412.0 thousand in the same period in 2024. The decrease in revenue was primarily due to the company's focus on advancing IGC-AD1, completing the Phase 2 clinical trial, and developing MINT-AD for early diagnosis of Alzheimer's disease, as well as a planned transition period linked to the disposition of its Vancouver manufacturing facility. Cost of revenue for the six months ended September 30, 2025, was about $266.0 thousand compared to $323.0 thousand in the prior year. The company reported a net loss of $1.8 million for the quarter, compared to a net loss of $1.7 million in the same period in 2024. During the quarter, IGC Pharma reached over 50% enrollment in its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-25-001752), on November 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.